Retatrutide and the Case for a Third Receptor

Most incretin research over the last decade has followed a clear line: agonise GLP-1, then add GIP. Retatrutide (LY3437943) breaks that pattern by adding a third receptor to the molecule — glucagon. It is the glucagon arm that makes it interesting, and also the part most often glossed over.

This piece covers what the third receptor actually contributes, what the published trial data shows, and the practical consequences for anyone designing in-vitro or preclinical work around the compound.

Three receptors, three different jobs

It helps to separate what each arm of the molecule is doing rather than treating "triple agonist" as a single mechanism.

• GLP-1 receptor. The best-characterised of the three. Glucose-dependent insulin secretion, slowed gastric emptying, and central signalling associated with reduced food intake.
• GIP receptor. The other incretin. Its contribution is still debated — agonism and antagonism have both produced metabolic benefit in different models, which is one of the genuinely unresolved questions in the field.
• Glucagon receptor. The addition. Glucagon receptor agonism raises energy expenditure and drives hepatic fat oxidation. On its own it would also raise blood glucose, which is precisely why it has to be paired with strong incretin agonism.

That pairing is the whole design. The glucagon arm supplies an energy-expenditure mechanism the other two do not have, and the GLP-1 arm offsets the glycaemic penalty that glucagon agonism would otherwise carry. Neither works without the other.

What the published data shows

The Phase 2 results published in the New England Journal of Medicine in 2023 are the reference point. Across 48 weeks, dose-dependent reductions in body weight were reported at magnitudes above those seen in comparable dual-agonist trials, alongside improvements in several metabolic markers.

Two caveats are worth carrying forward. Phase 2 populations are small and selected, so effect sizes routinely compress in Phase 3. And the adverse-event profile was dominated by gastrointestinal effects, consistent with the incretin class and closely tied to titration rate.

Practical notes for research use

Retatrutide behaves like other lyophilised peptides of its class, but a few points come up repeatedly:

• Dose-response curves need wide spacing. The three receptor arms do not have identical potency, so a narrow dose range can flatten a curve that is genuinely multiphasic.
• Species differences are real. Glucagon receptor pharmacology differs meaningfully between rodent and human receptors. Cross-species extrapolation is not straightforward here.
• Reconstituted stability is the usual constraint. Store lyophilised material cold and reconstitute close to use — see our reconstitution guide.

How it differs from the dual agonists

The useful comparison is against tirzepatide, which shares the GIP and GLP-1 arms and lacks the glucagon one. Set side by side, the design question becomes concrete: does adding glucagon receptor agonism buy anything that could not be obtained by simply pushing the two incretin receptors harder?

The theoretical argument for "yes" is that the mechanisms differ in kind, not just degree. Incretin agonism works substantially through reduced energy intake — satiety, slowed gastric emptying, central appetite signalling. Glucagon receptor agonism works on the other side of the equation, through energy expenditure and hepatic substrate handling. Two levers on opposite sides of energy balance should not be redundant.

The empirical argument is weaker, because no published trial isolates the variable. Retatrutide and tirzepatide differ in more than receptor coverage — potency at each receptor, pharmacokinetics and titration schedules all vary. Attributing the difference to the glucagon arm is reasonable but not demonstrated.

Reading the trial data critically

A few habits are worth applying to any report in this class:

• Check the completion rate. Gastrointestinal adverse events drive discontinuation in incretin trials, and per-protocol analyses of completers flatter a compound relative to intention-to-treat.
• Check the titration schedule. Slow titration improves tolerability and therefore completion. Two trials of the same molecule on different schedules are not directly comparable.
• Check the comparator arm. Against placebo, almost any effective incretin looks dramatic. Against a well-dosed active comparator, differences compress considerably.
• Watch for lean mass. Total body weight change is the headline number and the least informative one. Body composition, where reported, is more useful.

Designing around the compound

If you are building in-vitro work, a few constraints follow from the pharmacology:

• Choose a cell system that expresses all three receptors, or accept that you are characterising a subset. Many standard lines express one or two.
• Use a wide, log-spaced concentration range. Receptor arms of differing potency produce curves that a narrow range will render as a straight line.
• Include single- and dual-agonist comparators if the question is about the glucagon contribution. Without them, the experiment cannot answer it.
• Confirm receptor expression in your specific passage. Expression drifts with passage number more than most protocols acknowledge.

The open question

The field has not settled how much of the observed effect is attributable to the glucagon arm specifically, versus simply achieving greater total receptor engagement. Answering that requires selective antagonism studies that are still relatively thin in the published literature — which is exactly the gap independent research is positioned to fill.

Edit Labs supplies Retatrutide with a published certificate of analysis for every lot. For research use only.